Aqylon Nexus Ltd
AQYLONAqylon Nexus Ltd's balance sheet is under water — net worth is negative, so it owes more than it owns. The latest quarter's headline profit is a one-off item (larger than a full quarter's revenue), not money the business earned. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup.
The sharpest disagreement: the P/E sits at the 5th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (17 weeks in) while the P/E sits at the 5th percentile of its own 3-year range. But the balance sheet is under water: net worth is negative, so shareholders sit behind everyone the company owes. The latest quarter's profit is a one-off, not an operating recovery. What settles it: whether the business can earn its way back to positive equity before dilution or restructuring gets there first.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aqylon Nexus Ltd trades at ₹25.5, in a downtrend and 17 weeks into that stage. That is −67.1% against its own 200-day average. It sits at 0% of a 52-week range of ₹25 to ₹203. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (26 weeks and counting).
Today the stock is in a downtrend — week 17 of stage 4, confirmed. At ₹25.5 it trades −67.1% versus its 200-day average and sits at 0% of its 52-week range (₹25–₹203).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved −11% while the NIFTY 500 moved +257% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (26 weeks and counting; last ahead the week of 2026-02-20) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Aqylon Nexus Ltd trades at 4.9× P/E, near the bottom of its own range — cheaper only 5% of the time. Its long-run median P/E is 63.3×, measured across 2.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 4.9× is near the bottom of its own range — cheaper only 5% of the time, against a long-run median of 63.3× measured over 2.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aqylon Nexus Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
The return-on-capital curve is not shown — net worth is negative, so a return on capital is not a meaningful number in any basis. This is a distressed balance sheet, and the stage is read from the growth curves alone.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +100.0% | — | — | −24.7% |
| Share price | −75.3% | +453.9% | +156.4% | −0.4% |
4-Factor Sector Score
41.4/100 — rank 19 of 36 in Miscellaneous · 54% evidence confidence
Aqylon Nexus Ltd scores 41.4 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 19. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 12.7 + 16.8 + 8.7 + 3.2 = 41.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aqylon Nexus Ltd reported ₹0.0 Cr of revenue in the Jun 25 quarter, −97.2% year on year. Over 10 years it has compounded at −24.7% a year. The last full year, FY25, came in at ₹6.0 Cr. The last four reported quarters add to ₹5.0 Cr.
FY25 revenue came in at ₹6.0 Cr (+100.0% on the year), capping 10 years at −24.7% compound. The latest quarter (Jun 25) printed ₹0.0 Cr, −97.2% year on year.
Pace check: the last four quarters averaged +165.7% growth against the decade's −24.7% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aqylon Nexus Ltd's operating margin is −2,366.7% in the Jun 25 quarter, −2,377.7 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged −104.0% to 100.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −2,366.7%, −2,377.7 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged −104.0%–100.0%.
🚨 Why the margin moved: operating margin went −2,377.7 pp year on year while gross margin went −62.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aqylon Nexus Ltd posted a net loss of ₹1.9 Cr in the Jun 25 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY25 year was a loss of ₹22.0 Cr. That loss is 6,200.0% of the quarter's revenue.
Jun 25 profit was ₹−1.9 Cr, −3,820.0% year on year. On the full year, FY25 printed ₹−22.0 Cr (null).
🚨 Read this profit with care: at ₹−1.9 Cr it is larger than the whole quarter's revenue of ₹0.0 Cr — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −2,366.7% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 763% of Aqylon Nexus Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹6.0 Cr of operating cash against ₹−22.0 Cr of profit. After ₹−21.0 Cr of capital spending, ₹27.0 Cr was left as free cash.
FY25: operating cash of ₹6.0 Cr against reported profit of ₹−22.0 Cr, leaving free cash of ₹27.0 Cr after ₹−21.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 763% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 763%: the cash cycle tightened 39 days between FY17 and FY25 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aqylon Nexus Ltd's cash conversion cycle runs 28 days in FY25, down from 67 days in FY17. Capital spending ran ₹−66.0 Cr over the last 3 years. At FY25 sales of ₹6.0 Cr each day of that cycle holds about ₹0.0 Cr, so roughly ₹0.0 Cr sits inside the business at any moment.
FY25: debtors at 28 days, inventory at 0 days — roughly 0.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 28 days, tighter than FY17's 67.
In money terms: at FY25 sales of ₹6.0 Cr, each day of the cycle holds about ₹0.0 Cr — so the 28-day loop keeps roughly ₹0.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−66.0 Cr over the last 3 fiscal years against ₹39.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹10.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Aqylon Nexus Ltd earns a ROCE of 39% in FY25. That is up from a trough of −103% in FY19. Return on invested capital clears the cost of that capital by −3.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −366.7% net margin on 0.11× asset turns.
FY25 ROCE is 39%, recovered from a FY19 trough of −103% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −366.7% net margin × 0.11× asset turns × −5.00× balance-sheet leverage ≈ 201.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 9.0% − 12.0% = a −3.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Aqylon Nexus Ltd's net worth is negative — it owes more than it owns — so a debt-to-equity ratio is not meaningful here. On the annual view that ratio went from −2.32 in FY22 to −3.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹18.0 Cr against shareholder equity of ₹−6.0 Cr — a debt-to-equity of −3.00. On the annual view, debt-to-equity went from −2.32 (FY22) to −3.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 27.4 points of Aqylon Nexus Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 27.6% of the company. Promoters moved −13.9 points over the same window, to 45.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +27.4 points over 8 quarters to 27.6%; Promoters: −13.9 points over 8 quarters to 45.6%; Foreign institutions: +8.4 points over 8 quarters to 8.4%.
Why the register moved: domestic institutions drove it (+27.4 points), absorbed on the other side by promoters (−13.9 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aqylon Nexus Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1IIRM Holdings India Ltd526530 | 66.2/100Favorable setup71% evidence | LEADER | 17.7/35 Revenue 14.9% · PAT 12.7% · OPM change 8.4 pp 83% evidence | 19.1/25 ROCE 20.4% · OPM 24.8% 76% evidence | 9.7/20 P/E 40.4× · PEG — 15% evidence | 19.7/20 RS sector 49.6% · RS bench 53.5% · 1Y 67.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 19.1 + 9.7 + 19.7 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 66.1/100Favorable setup87% evidence | TURNING | 24.4/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.5/25 ROCE 13.4% · OPM 22% 100% evidence | 14.2/20 P/E 19.8× · PEG 1.05 65% evidence | 12.0/20 RS sector 7.2% · RS bench -5% · 1Y -1.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 24.4 + 15.5 + 14.2 + 12 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Gulshan Polyols LtdGULPOLY | 65.2/100Favorable setup75% evidence | TURNING | 24.8/35 Revenue 35.2% · PAT 87% · OPM change 4.3 pp 59% evidence | 12.3/25 ROCE 6.3% · OPM 8% 95% evidence | 10.5/20 P/E 28.9× · PEG — 50% evidence | 17.6/20 RS sector 16.1% · RS bench 19.4% · 1Y 16.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 12.3 + 10.5 + 17.6 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 64.4/100Thin evidence · provisional60% evidence | ASLEEP | 19.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.6/20 P/E 19.2× · PEG — 50% evidence | 11.4/20 RS sector 2.2% · RS bench -1.2% · 1Y -7.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.1 + 13.6 + 11.4 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5GMR Airports LtdGMRAIRPORT | 59.8/100Mixed-positive evidence71% evidence | BREAKING OUT | 22.8/35 Revenue 42.2% · PAT 100% · OPM change 2 pp 65% evidence | 14.2/25 ROCE 11.6% · OPM 37% 100% evidence | 8.6/20 P/E 534× · PEG — 15% evidence | 14.2/20 RS sector 3.3% · RS bench 6.5% · 1Y 17.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 14.2 + 8.6 + 14.2 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Aeroflex Enterprises LtdAEROENTER | 59.3/100Mixed-positive evidence83% evidence | LEADER | 16.8/35 Revenue 20.4% · PAT 4.9% · OPM change 1 pp 83% evidence | 16.0/25 ROCE 12.6% · OPM 18% 95% evidence | 8.1/20 P/E 20.9× · PEG — 50% evidence | 18.4/20 RS sector 24.8% · RS bench 28.1% · 1Y 16%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 16 + 8.1 + 18.4 = 59.3 · Decision use: Price leads the evidence: RS versus the benchmark is 28.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Global Education LtdGLOBAL | 59.3/100Mixed-positive evidence76% evidence | ASLEEP | 16.6/35 Revenue 29.9% · PAT -5.5% · OPM change 7.5 pp 83% evidence | 19.4/25 ROCE 29.2% · OPM 47% 95% evidence | 10.8/20 P/E 20× · PEG — 15% evidence | 12.5/20 RS sector 12.5% · RS bench 15.9% · 1Y 56.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 19.4 + 10.8 + 12.5 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Take Solutions LtdTAKE | 58.9/100Mixed-positive evidence63% evidence | 25.1/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.3/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 68% · RS bench 71.4% · 1Y 305.2%11 of 12 weeks ahead to 2026-05-03 100% evidence | |
| Exact sum: 25.1 + 8.3 + 8.5 + 17 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9R K Swamy LtdRKSWAMY | 58.5/100Mixed-positive evidence61% evidence | TURNING | 22.5/35 Revenue 15.9% · PAT 21.1% · OPM change 3 pp 83% evidence | 16.9/25 ROCE 12.3% · OPM 22% 95% evidence | 10.4/20 P/E 21.2× · PEG — 15% evidence | 8.7/20 RS sector — · RS bench -11.2% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 22.5 + 16.9 + 10.4 + 8.7 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jai Corp LtdJAICORPLTD | 57.6/100Mixed-positive evidence70% evidence | ASLEEP | 24.1/35 Revenue -0.6% · PAT 100% · OPM change 5 pp 83% evidence | 15.3/25 ROCE 13.3% · OPM 13% 95% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 6.7/20 RS sector -8.2% · RS bench -18.9% · 1Y -1.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 24.1 + 15.3 + 11.5 + 6.7 = 57.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.2% and the one-year return is -1.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Aegis Vopak Terminals LtdAEGISVOPAK | 56.0/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 25.6% · PAT 76.7% · OPM change 2 pp 83% evidence | 13.4/25 ROCE 7.6% · OPM 74% 76% evidence | 9.1/20 P/E 104× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 22% · 1Y 13%5 of 10 weeks ahead 25% evidence |
| Exact sum: 21.4 + 13.4 + 9.1 + 12.1 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Parin Enterprises LtdPARIN | 54.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 19.7/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.7/25 ROCE 10.8% · OPM 9% 95% evidence | 9.0/20 P/E 123× · PEG — 15% evidence | 13.9/20 RS sector 13.1% · RS bench 16.5% · 1Y 94.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 11.7 + 9 + 13.9 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Inox Green Energy Services LtdINOXGREEN | 50.7/100Mixed-positive evidence65% evidence | ASLEEP | 24.7/35 Revenue 24.6% · PAT 100% · OPM change 0.5 pp 83% evidence | 9.5/25 ROCE 8.4% · OPM -4.1% 76% evidence | 9.3/20 P/E 66× · PEG — 15% evidence | 7.2/20 RS sector -8.6% · RS bench -8.4% · 1Y -1.1%6 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 9.5 + 9.3 + 7.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Eveready Industries India LtdEVEREADY | 48.3/100Mixed-negative evidence90% evidence | TURNING | 17.6/35 Revenue 8.2% · PAT 100% · OPM change 0 pp 88% evidence | 14.9/25 ROCE 17.2% · OPM 9% 100% evidence | 8.1/20 P/E 24.9× · PEG 2.1 100% evidence | 7.7/20 RS sector -9.5% · RS bench -3% · 1Y -19.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 17.6 + 14.9 + 8.1 + 7.7 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15TCC Concept LtdTCC | 47.3/100Mixed-negative evidence81% evidence | ASLEEP | 17.3/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.4/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20.9× · PEG — 50% evidence | 4.5/20 RS sector -17.6% · RS bench -35% · 1Y -44.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.3 + 11.4 + 14.1 + 4.5 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16GKW LtdGKWLIMITED | 46.7/100Mixed-negative evidence63% evidence | ASLEEP | 20.7/35 Revenue -2.1% · PAT 87.5% · OPM change 2160.4 pp 83% evidence | 6.7/25 ROCE 0.5% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.3/20 RS sector -0.9% · RS bench -5% · 1Y -8.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 20.7 + 6.7 + 10 + 9.3 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 43.4/100Mixed-negative evidence68% evidence | ASLEEP | 21.2/35 Revenue 9.2% · PAT 100% · OPM change 23 pp 62% evidence | 11.2/25 ROCE 6.1% · OPM 34.5% 95% evidence | 9.6/20 P/E 59.4× · PEG — 15% evidence | 1.4/20 RS sector -23% · RS bench -20.5% · 1Y -0.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11.2 + 9.6 + 1.4 = 43.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Jindal Photo LtdJINDALPHOT | 41.5/100Mixed-negative evidence67% evidence | ASLEEP | 14.6/35 Revenue 100% · PAT -80% · OPM change -1015.9 pp 83% evidence | 5.9/25 ROCE -1.4% · OPM -932.6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.0/20 RS sector 6.3% · RS bench -13.8% · 1Y 23.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 5.9 + 10 + 11 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Aqylon Nexus Ltdthis pageAQYLON | 41.4/100Thin evidence · provisional54% evidence | ASLEEP | 12.7/35 Revenue 30.8% · PAT -52.5% · OPM change -2377.7 pp 48% evidence | 16.8/25 ROCE 39.2% · OPM — 80% evidence | 8.7/20 P/E 168.9× · PEG — 15% evidence | 3.2/20 RS sector -41.3% · RS bench -74.1% · 1Y -68.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.7 + 16.8 + 8.7 + 3.2 = 41.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Kaveri Seed Company LtdKSCL | 41.2/100Mixed-negative evidence82% evidence | ASLEEP | 18.1/35 Revenue 15.9% · PAT 5% · OPM change 3 pp 65% evidence | 12.6/25 ROCE 18.8% · OPM -15% 100% evidence | 5.1/20 P/E 13.6× · PEG 2.98 100% evidence | 5.4/20 RS sector -17.2% · RS bench -18.7% · 1Y -30.4%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.1 + 12.6 + 5.1 + 5.4 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21TruAlt Bioenergy LtdTRUALT | 40.8/100Mixed-negative evidence63% evidence | ASLEEP | 11.1/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.4/25 ROCE 10.8% · OPM 21% 100% evidence | 10.3/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 11.1 + 9.4 + 10.3 + 10 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Delta Corp LtdDELTACORP | 38.6/100Mixed-negative evidence77% evidence | ASLEEP | 11.2/35 Revenue -6.5% · PAT -66.4% · OPM change -5 pp 83% evidence | 9.6/25 ROCE 5% · OPM 17% 95% evidence | 12.5/20 P/E 18.9× · PEG — 50% evidence | 5.3/20 RS sector -18.1% · RS bench -11.6% · 1Y -28.9%6 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 9.6 + 12.5 + 5.3 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Shipping Corporation of India Land & Assets LtdSCILAL | 33.7/100Adverse evidence68% evidence | ASLEEP | 15.6/35 Revenue 27.3% · PAT 100% · OPM change -284.4 pp 62% evidence | 4.7/25 ROCE 1.3% · OPM -349.6% 95% evidence | 9.2/20 P/E 66.6× · PEG — 15% evidence | 4.2/20 RS sector -15.5% · RS bench -12.7% · 1Y -19.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 4.7 + 9.2 + 4.2 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Unitech LtdUNITECH | 32.0/100Adverse evidence65% evidence | ASLEEP | 12.8/35 Revenue 59% · PAT 5% · OPM change -584 pp 62% evidence | 6.1/25 ROCE 0.1% · OPM 184% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.1/20 RS sector -27.3% · RS bench -24.8% · 1Y -42.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.1 + 10 + 3.1 = 32 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Stanley Lifestyles LtdSTANLEY | 31.5/100Adverse evidence70% evidence | TURNING | 8.4/35 Revenue -1.6% · PAT -55.5% · OPM change -5.2 pp 83% evidence | 10.3/25 ROCE 6.4% · OPM 14.9% 95% evidence | 9.5/20 P/E 62.7× · PEG — 15% evidence | 3.3/20 RS sector -43.7% · RS bench -23.7% · 1Y -53.6%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.4 + 10.3 + 9.5 + 3.3 = 31.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26RattanIndia Enterprises LtdRTNINDIA | 29.3/100Adverse evidence62% evidence | ASLEEP | 13.8/35 Revenue 5.4% · PAT -80% · OPM change 19 pp 65% evidence | 1.6/25 ROCE -4.8% · OPM -6% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -32.1% · RS bench -23% · 1Y -45%6 of 10 weeks ahead 70% evidence |
| Exact sum: 13.8 + 1.6 + 10 + 3.9 = 29.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence68% evidence | BREAKING OUT | 4.3/35 Revenue -20.6% · PAT -80% · OPM change -76.9 pp 83% evidence | 3.6/25 ROCE -2.4% · OPM -76% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -17.2% · RS bench -14.6% · 1Y -45.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 4.3 + 3.6 + 10 + 8.3 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Central Mine Planning & Design Institute LtdCMPDI | 62.2/100Thin evidence · provisional38% evidence | TURNING | 22.3/35 Revenue — · PAT — · OPM change 8 pp 32% evidence | 19.8/25 ROCE 38.1% · OPM 30% 95% evidence | 10.1/20 P/E 26.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 22.3 + 19.8 + 10.1 + 10 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29FlySBS Aviation LtdFLYSBS | 54.7/100Thin evidence · provisional41% evidence | TURNING | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 18.9/25 ROCE 32.5% · OPM 21% 95% evidence | 11.4/20 P/E 13.3× · PEG — 15% evidence | 9.0/20 RS sector — · RS bench -6.8% · 1Y 4.4%3 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 18.9 + 11.4 + 9 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Qualitek Labs Ltd544091 | 53.7/100Thin evidence · provisional29% evidence | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.0/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 33.6× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 9.1% · 1Y — 25% evidence | |
| Exact sum: 17.3 + 15 + 9.8 + 11.6 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Shree Vasu Logistics LtdSVLL | 51.9/100Thin evidence · provisional48% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 2.6 pp 19% evidence | 15.7/25 ROCE 12.9% · OPM 29% 95% evidence | 8.9/20 P/E 144× · PEG — 15% evidence | 8.9/20 RS sector -16.1% · RS bench 5.1% · 1Y -8.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 18.4 + 15.7 + 8.9 + 8.9 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Maagh Advertising & Marketing Services Ltd543624 | 49.6/100Thin evidence · provisional35% evidence | 18.3/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.0/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.3/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.3 + 9 + 10 + 12.3 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces LtdINDIQUBE | 49.3/100Thin evidence · provisional46% evidence | ASLEEP | 20.9/35 Revenue 36.9% · PAT 23.6% · OPM change 5 pp 62% evidence | 9.6/25 ROCE 6.4% · OPM 62% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.8/20 RS sector — · RS bench -9.8% · 1Y -20.2%2 of 10 weeks ahead 25% evidence |
| Exact sum: 20.9 + 9.6 + 10 + 8.8 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Anzen India Energy Yield Plus TrustANZEN | 47.7/100Thin evidence · provisional46% evidence | ASLEEP | 17.4/35 Revenue 76.8% · PAT 100% · OPM change -9 pp 62% evidence | 8.9/25 ROCE 3.3% · OPM 75.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.4/20 RS sector — · RS bench 5.7% · 1Y 9.6%4 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 8.9 + 10 + 11.4 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Shree Rama Newsprint LtdRAMANEWS | 44.6/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 5.7/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 7.4% · RS bench 10.5% · 1Y 8.8%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 5.7 + 10 + 14.8 = 44.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Tandhan Industries Ltd512062 | 42.6/100Thin evidence · provisional33% evidence | TURNING | 16.3/35 Revenue — · PAT -80% · OPM change — 50% evidence | 6.3/25 ROCE -0.3% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 16.3 + 6.3 + 10 + 10 = 42.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aqylon Nexus Ltd's share price today?
Aqylon Nexus Ltd trades at ₹25.5, −75.3% over the past year. The company is valued at ₹647 Cr. The stock sits at 0% of its 52-week range of ₹25–₹203, −67.1% versus its 200-day average. On the tape, the price is in a downtrend, 17 weeks in. — as of 31 July 2026.
What were Aqylon Nexus Ltd's latest quarterly results?
Aqylon Nexus Ltd reported revenue of ₹0.0 Cr and a net loss of ₹1.9 Cr for the Jun 25 quarter. Revenue fell 97.2% and profit fell 3,820.0% year on year. Earnings per share were ₹−0.07. The operating margin was −2,366.7%, 2,377.7 pp lower than a year earlier. — as of 31 July 2026.
What is Aqylon Nexus Ltd's revenue?
Aqylon Nexus Ltd reported revenue of ₹0.0 Cr in the Jun 25 quarter, −97.2% year on year. For the full FY25 fiscal year, revenue was ₹6.0 Cr (+100.0%). Over the last 10 years revenue compounded at −24.7% a year. — as of 31 July 2026.
What is Aqylon Nexus Ltd's profit?
Aqylon Nexus Ltd earned ₹−1.9 Cr of net profit in the Jun 25 quarter, −3,820.0% year on year. Full-year FY25 profit was ₹−22.0 Cr. The operating margin ran −2,366.7% in the latest quarter. — as of 31 July 2026.
What is Aqylon Nexus Ltd's market cap?
Aqylon Nexus Ltd's market capitalisation is ₹647 Cr at a share price of ₹25.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Aqylon Nexus Ltd's P/E ratio?
Aqylon Nexus Ltd trades at a P/E of 4.9×, at the 5th percentile of its own 3-year range, against a long-run median of 63.3×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Aqylon Nexus Ltd pay a dividend?
Not in its latest year — Aqylon Nexus Ltd's dividend payout was 0% of profit in FY25. It did record a payout in 4 of its last 12 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Aqylon Nexus Ltd overvalued?
On its own history, Aqylon Nexus Ltd looks cheap against its own history: its P/E of 4.9× has been cheaper only 5% of the time in 3 years (long-run median 63.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Aqylon Nexus Ltd growing?
Not right now — Aqylon Nexus Ltd's latest numbers are shrinking: latest-quarter revenue −97.2% year on year, profit −3,820.0%, and the margin −2,377.7 pp at −2,366.7%. The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Aqylon Nexus Ltd performing?
Aqylon Nexus Ltd is in a downtrend, 17 weeks in. Its latest quarter's revenue fell 97.2% and profit fell 3,820.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 26 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Aqylon Nexus Ltd in an uptrend?
No — the price is in a downtrend (week 17 of stage 4), trading −67.1% versus its 200-day average and at 0% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Aqylon Nexus Ltd beating the market?
Not lately — on a trailing-13-week view Aqylon Nexus Ltd is currently behind the NIFTY 500 (26 weeks and counting; last ahead the week of 2026-02-20), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved −11% against the NIFTY 500's +257% — behind the index over the full window. — as of 31 July 2026.
Will Aqylon Nexus Ltd's share price go up?
This page publishes no price forecast for Aqylon Nexus Ltd. What it measures instead: the share price is ₹25.5, the price is in a downtrend 17 weeks in. Its P/E of 4.9× sits at the 5th percentile of its own 3-year range. — as of 31 July 2026.
Who owns Aqylon Nexus Ltd?
Promoters hold 45.6% of Aqylon Nexus Ltd, foreign institutions 8.4%, domestic institutions 27.6% and the public 18.4% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 27.4 points over 8 quarters. — as of 31 July 2026.
Does Aqylon Nexus Ltd have too much debt?
No — Aqylon Nexus Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill −0×. FY25 borrowings were ₹0.0 Cr against equity of ₹−11.0 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Aqylon Nexus Ltd's capex?
Aqylon Nexus Ltd spent ₹−66.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹−21.0 Cr, with ₹10.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Aqylon Nexus Ltd's cash flow?
Aqylon Nexus Ltd generated ₹6.0 Cr of operating cash flow in FY25 and ₹27.0 Cr of free cash flow after ₹−21.0 Cr of capital spending. Reported profit that year was ₹−22.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Aqylon Nexus Ltd's profit real cash?
Yes — over the last 3 fiscal years, 763% of Aqylon Nexus Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹6.0 Cr against reported profit of ₹−22.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Aqylon Nexus Ltd in its business cycle?
Aqylon Nexus Ltd's FY25 operating margin was 6.0%, against a 9-year band of −104.0%–100.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −2,366.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Aqylon Nexus Ltd story?
The sharpest disagreement: the P/E sits at the 5th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Aqylon Nexus Ltd a stock worth studying right now?
This is not investment advice. The machine read: Aqylon Nexus Ltd's balance sheet is under water — net worth is negative, so it owes more than it owns. The latest quarter's headline profit is a one-off item (larger than a full quarter's revenue), not money the business earned. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup. The sharpest open question: whether the business can earn its way back to positive equity before dilution or restructuring gets there first. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.